Quantum AI vaccine takes on brain cancer in first human trial
NCT ID NCT07077616
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 21 times
Summary
This early-phase trial tests a personalized vaccine called Tamavaq NeoVaccine in 29 adults with newly diagnosed glioma, a type of brain cancer. The vaccine is custom-made using AI and quantum mechanics to target unique mutations in each patient's tumor. The main goal is to check if the vaccine is safe and to monitor side effects like fever, headache, and injection site reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Biogenea Pharmaceuticals Ltd
RECRUITINGThessaloniki, 54627, Greece
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.